Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2010

PerkinElmer and LinaTech to Offer Imaging Solutions for Cancer Treatment

  • PerkinElmer entered into a joint technology development and marketing agreement with LinaTech. The companies will develop, implement, market and distribute imaging technologies for the treatment of various cancers.

    The proposed products will include cost-effective imaging solutions that allow customers to upgrade their legacy film-based radiotherapy systems. They will also incorporate imaging subsystems for sales to radiotherapy system manufacturers.

    “We look forward to very compelling outcomes from our development project, as we seek to create new technologies for the benefit of cancer patients by giving doctors and hospitals more imaging options,” says Brian Giambattista, president, medical imaging, PerkinElmer.

    A first-generation imaging product, the FDA 510k-approved LinaTech TiGRT Image Viewing System, will be showcased at the American Society of Therapeutic Radiology and Oncology in San Diego. It is a Patient Position Verification and Electronic Portal Imaging Device system and is used for patient position verification, patient tumor tracking and localization, portal verification and record, dynamic MLC leaf detection, dosimetry verification, and exist dose recording.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »